昆药集团股份有限公司简介

  

  昆药集团股份有限公司(简称昆药集团 600422 SH)成立于1951年3月,2000年12月,在上海证券交易所上市。公司拥有深厚的专业制药经验,是国家重点高新技术企业、中国医药工业百强企业。自有品牌络泰®、天眩清®、Artemedine®、Artem®、Arco®等享誉国内外。
  昆药集团集药物研发、生产、销售、商业批发和国际营销为一体,形成了以自主天然植物药为主,涵盖中药、化学药和医药流通领域的业务格局。旗下拥有昆明中药厂有限公司、昆药集团血塞通药业股份有限公司、西双版纳版纳药业有限责任公司、昆明制药集团医药商业有限公司、昆明贝克诺顿制药有限公司、昆药集团努库斯植物技术有限公司、昆明银诺医药技术有限公司、北京华方科泰医药有限公司等参控股公司,并拥有规模化制造中心、血塞通药物研究院和博士后工作站。落地昆明高新区国家生物产业基地的 “昆药生物医药科技园”,建成后将成为世界领先、国内一流的规模化、专业化、国际化生物医药园区。
  依托云南丰富的植物资源,昆药集团先后开发了青蒿系列、三七系列、天麻系列及特色中药、特色民族药等40多个具有国内外先进水平的天然植物药新产品,拥有多项国家发明专利,填补了多项国内外空白,在心脑血管、神经系统、疟疾等疾病治疗领域拥有较高的知名度与美誉度,为人类的健康事业做出了积极、重大的贡献。  
  突出的研发实力、丰富的产品资源、强大的综合制造系统、与国际接轨的质量管理体系、国际化的营销队伍共同构成了昆药集团不可替代的核心竞争优势。在未来的发展中,昆药集团将以“绿色昆药、福祉社会”为宗旨,发展成为聚焦心脑血管,专注慢病领域的国际化药品提供商,力争成为全球心脑血管药物的知名品牌和杰出代表


  KPC Pharmaceuticals, Inc (hereinafter be abbreviated as ‘KPC’, 600422 SH) was established in March 1951 and floated on the Shanghai Stock Exchange in December 2000. With its considerable professional experience in pharmaceutical industry, the company is listed as one of the new key national high-tech companies and one of the Top 100 companies in the Chinese medical industry. The company’s brands such as Luotai®, Tianxuanqing®, Artemedine®, Artem® and Arco® currently enjoy a good reputation both at home and abroad.
  
  KPC is a pharmaceutical company which focused on innovative natural botanical drugs and integrates R&D, production, marketing, commercial wholesales and international marketing. Its business scope covers traditional Chinese medicine, chemical medicine and medicinal circulation. Companies owned by KPC include the Kunming Traditional Chinese Medicine Co. Ltd.,
 
  Xuesaitong Pharmaceutical Co., Ltd., Xishuangbanna Pharmaceutical Co. Ltd.,
 
  Kunming Pharmaceutical Commercial Co. Ltd., Kunming Baker Norton Pharmaceutical Co. Ltd., Nukus Botanic Technology Co. Ltd., Kunming Yinnuo Medical Technology Co. Ltd., and Beijing Holley-Cotec Pharmaceuticals Co. Ltd. KPC also boasts a large-scale manufacturing center, Xuesaitong drug research institute and postdoctoral workstation. Situated in the National Biological Industry Base of the Kunming High-tech Zone, the "KPC Bio-Pharmaceutical Science and Technology Park" will be a large-scale, professional and international biomedical park, taking the lead both at home and abroad.
  
  Based on Yunnan’s abundant plant resources, KPC has developed more than 40 new natural botanical drugs, including the artemether series, panax notoginseng series, gastrodine series, special Chinese medicines and special ethnic drugs. With multiple national patents, KPC has filled several gaps in the pharmaceutical industry both at home and abroad. Being highly renowned and popular in terms of treatments for cardio-cerebral-vascular diseases, nervous system diseases and malaria, KPC has made positive and significant contributions to the health of human.
  
  KPC's unique core competitive advantages include its outstanding R&D ability, abundant product resources, strong integrated manufacturing system, internationally compatible quality management system and its international marketing team. In the future, following the principle "From nature; For Human Health", KPC will develop into an international pharmaceutical supplier focusing on cardio-cerebral-vascular disease and chronic disease treatment. At the same time, it will continue striving to be an outstanding and globally famous brand in terms of cardio-cerebral-vascular drugs.
  
 

联系方式:大会秘书处(孙媛媛) 13910522140 | 邮箱 zgnbdh@163.com | 北京市朝阳区慧忠北里105号B段京师科技大厦5层

主办单位:中国中药协会脑病药物研究专业委员会  版权所有:中国中药协会脑病药物研究专业委员会

Copyright © 2019 www.ccobd.org 欢迎访问中国脑病大会官网 All Rights Reserved  京ICP:34477534